---
title: Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients
nct_id: NCT01237275
overall_status: UNKNOWN
phase: NA
sponsor: Samsung Medical Center
study_type: INTERVENTIONAL
primary_condition: Depression
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01237275.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01237275"
ct_last_update_post_date: 2015-12-31
last_seen_at: "2026-05-12T07:14:39.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients

**NCT ID:** [NCT01237275](https://clinicaltrials.gov/study/NCT01237275)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 300
- **Lead Sponsor:** Samsung Medical Center
- **Conditions:** Depression, Continuous Antidepressant Abuse, Adverse Reaction to Drug
- **Start Date:** 1999-10
- **Completion Date:** 2016-12
- **CT.gov Last Update:** 2015-12-31

## Brief Summary

First, the investigators examined the functional relevance of serotonin transporter polymorphisms by quantifying the activity of serotonin transporter in blood platelets of genotyped healthy volunteers and patients with major depression.

Second, the investigators studied response to SSRIs in relation to 5-HTTLPR genotype and also to the functional expression of 5-HTT in platelets.

## Detailed Description

The purpose of this study is

1. to determine whether serotonin transporter genotypic or functional differences between depressive patients and normal controls were existed.
2. to determine the relationship between serotonin transporter polymorphisms and serotonin transporter functional expression.
3. to determine whether genomic or functional differences between drug responders and nonresponders predict the response of antidepressant

## Eligibility

- **Minimum age:** 19 Years
- **Maximum age:** 89 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Eligible patients were enrolled in the clinical trials program of hte Samsung Medical Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the Korean version of the structured clinical interview for the diagnostic and statistical manual of mental disorders, Fourth edition.
* interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians

Exclusion Criteria:

* received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks
* potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.
```

## Arms

- **SSRI treated group** (EXPERIMENTAL) — SSRI treated group are depressive patients treated with fluoxetine, paroxetine or sertraline

## Interventions

- **SSRI treated group** (DRUG) — characterize in arm of a study (SSRI treated group)

## Primary Outcomes

- **Antidepressant Response at 2,4,6 weeks** _(time frame: 6 weeks)_

## Secondary Outcomes

- **Biological value at 0 and 6 weeks** _(time frame: 6weeks)_

## Locations (1)

- Samsung Medical Center, Kangnam, Seoul, South Korea

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.samsung medical center|kangnam|seoul|south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01237275.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01237275*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*